Nature Communications
An open access, multidisciplinary journal dedicated to publishing high-quality research in all areas of the biological, health, physical, chemical and Earth sciences.
Towards more affordable pneumococcal vaccines
Check out how we are developing an alternative, streamlined method for manufacturing pneumococcal conjugate vaccines all within the lab safe, bacterium E. coli…
Immunotherapy against cancer to be used in HIV cure strategy: a proof-of-concept
In the era of suppressive antiretroviral therapy (ART), HIV reservoir cells are the last hurdle in eradicating the virus. Here, we are testing the hypothesis that immunotherapy against cancer potentiates the reactivation of latently infected cells isolated from ART-suppressed individuals favoring their elimination.
Harnessing insights from one child case of post-treatment control of HIV
Individuals who have the ability to control HIV-1 to undetectable levels either naturally in the absence of antiretroviral treatment (ART) (elite controllers), or those who achieve this after starting ART early in infection and later stopping ART (post-treatment controllers) – tell us that HIV remission is possible. This study describes virological and immunological features associated with a single case of durable post-treatment control of HIV-1 in a young South African child.
